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Transcription Factor EB (TFEB), a master regulator of lysosomal biogenesis and 
autophagy, regulates liver glucose and lipid metabolism in response to nutrients. Here 
we show that TFEB also plays an important role in cell lineage specification and 
proliferation both during development and upon liver regeneration. In vitro and in vivo 
gain- and loss-of function studies revealed that TFEB drives the differentiation status 
of liver progenitor cells (LPCs) into the progenitor/cholangiocyte lineage while 
inhibiting differentiation into the hepatocyte lineage. Accordingly, TFEB liver-specific 
overexpressing mice showed cells with hybrid features of hepatocytes and LPCs, 
ectopic bile duct formation, cholestasis and bile duct neoplasms. On the contrary, 
TFEB conditional KO mice in the liver exhibited an aberrant response to hepatic injury 
characterized by depressed LPC expansion. Genetic interaction studies showed that 
Sox9, marker of precursor and biliary cells, is a direct TFEB target and a primary 
mediator of its effects on liver cell fate.  In summary, our findings reveal a previously 
unrecognized role for TFEB in controlling cell lineage commitment and identify a novel 
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unexplored pathway that is involved in liver homeostasis and may play a role in biliary 
cancer.  
Introduction 
The adult liver is the largest internal organ and provides many essential metabolic, exocrine, 
and endocrine functions1. Being a complex organ with several cell types, liver development 
involves multiple cell fate decisions. For instance, during development hepatic endoderm cells, 
known as hepatoblasts (HBs), differentiate into hepatocytes or cholangiocytes depending on 
their localization with respect to the portal vein: HBs exposed to ligands from portal venous 
endothelial cells differentiate into primitive ductal plate cells and then form bile ducts, whereas 
HBs located further away from the portal vein differentiate into hepatocytes2,3. Hepatocytes in 
the adult liver rarely divide, however, under conditions in which alterations of liver mass 
occurs, such as surgical removal or cell loss caused by drugs or viruses, quiescent 
hepatocytes become proliferative and replicate to restore full liver functional capacity4. In 
certain injury models, hepatocytes can transdifferentiate into ductal biliary epithelial cells 
(BECs) to ensure tissue regeneration5-9. However, when hepatocyte proliferation is 
compromised, BECs become active and subsequently differentiate into hepatocytes10,11. Liver 
stem/progenitor cells (LPCs) may appear in chronic liver damage when hepatocyte 
proliferation is compromised and differentiate in both hepatocytes and bile ducts12. In humans, 
LPCs are evident in pathological ductular reactions often observed in a variety of liver 
diseases, including fatty liver diseases2, chronic viral hepatitis13, cirrhosis14 and acute hepatic 
injury15. Thus, LPCs are considered potential targets for liver cell transplantation and 
repopulation16,17. However, although LPCs have capacity to differentiate into hepatocytes and 
biliary cells in vitro and to form hepatocytes buds repopulating the liver in vivo18, their ability 
to participate to liver regeneration in human clinical setting is still unclear19,20. A specialized 
type of cells with both LPCs and mature hepatocytes features, called hybrid hepatocytes 
(HybHPs), express both SRY (sex determining region Y)-box (SOX9), a marker of LPCs, and 
the hepatocyte marker hepatocyte nuclear factor 4α (HNF4α) 21. HybHPs are located at the 
periportal region of normal liver and are efficient in liver repair when non-centrilobular 
hepatocytes are damaged. Thus, it appears that liver injury triggers several regenerative 
responses depending on the size and the proliferative capacity of the remaining liver tissue22.  
The mechanisms regulating liver cell proliferation and differentiation are highly controlled to 
achieve accurate tissue growth and development, and deregulation of the signaling pathways 
involved in liver cell differentiation can impair regeneration and trigger the development of 
tumors with hepato-cellular and cholangio-cellular differentiation features23,24. Thus, a better 
understanding of the processes that control liver cell differentiation in physiological and 
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pathological conditions may contribute to the identification of novel and druggable targets and 
represent a potential therapeutic approach for the treatment of liver diseases.    
Transcription factor EB (TFEB) belongs to the MiT-TFE family of transcription factors, which 
also includes MITF, TFE3, and TFEC25. In the last decade, several studies have explored the 
role of TFEB in physiological settings and in response to environmental cues. TFEB was first 
described as essential for placental vascularization26. Subsequently, TFEB has been 
implicated in the expression of lysosomal and autophagic genes27,28. TFEB is phosphorylated 
by the mTOR kinase and participates in a lysosomal signaling mechanism that is essential for 
nutrient sensing and maintenance of cellular homeostasis and energy metabolism29-31. In 
addition, TFEB has an important role in the regulation of body metabolism in liver and muscle 
and in the adaptation to environmental cues (e.g. fasting, high-fat diet, exercise)32,33. 
Furthermore, overexpression of MiT-TFE genes has been implicated in the pathogenesis of a 
variety of tumors, including renal cell carcinoma, melanoma, and pancreatic cancer34-37, 
suggesting their involvement in cell differentiation and proliferation. However, a role of TFEB 
in cell fate determination and liver cancer has not been investigated so far.   
Here, we show that TFEB plays a critical role in controlling cell fate and proliferation in the 
mammalian liver during embryogenesis and repair. Indeed, we found that TFEB is highly 
expressed in LPCs and BECs and that genetic manipulation of TFEB expression in the liver 
alters cell lineage specification in both developing and injured adult liver. Our data identify 
Sox9 as one important downstream target of TFEB in hepatic cell differentiation, highlighting 
the importance of this pathway in liver development, regeneration and cancer. 
Results 
TFEB is highly expressed in the biliary compartment 
To investigate whether TFEB plays a role in liver development, we examined its expression 
during liver specification. We used a mouse line in which the endogenous Tcfeb allele is 
disrupted by homologous recombination at exons 4 and 5 through the insertion of the β-
Galactosidase coding sequence29 (Supplementary Fig. 1a). Since TcfebKO mice are 
embryonic lethal26,29, heterozygous embryos (TcfebLacZ/+) were collected at several embryonic 
stages to analyze Tcfeb promoter activity. Tcfeb expression was detected in the liver starting 
at embryonic stage E14.5 and increases overtime, just prior to the developmental 
differentiation of HBs into hepatocytes or biliary epithelial cells (BECs)1, while no expression 
was detected at E12.5 (Supplementary Fig. 1b). Consistent with these results, the 
expression of the endogenous Tcfeb mRNA and protein expression levels in fetal and 
neonatal livers showed a gradual increase during liver growth (Supplementary Fig. 1c and 
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1d). Immunostaining analysis revealed a dynamic expression pattern of TFEB during liver 
development. At E15.5 TFEB was diffuse in the entire parenchyma (Fig. 1a). At postnatal 
stage P0 and adult stage, a stronger expression was detected in the portal vein endothelium 
(Fig. 1a and 1b), while pericentral hepatocytes (adjacent to the central vein) showed low and 
diffuse TFEB expression (Fig. 1b). Indeed, TFEB was mainly detected in HNF4α-/SOX9+ 
ductal plate cells and mature ducts (Fig. 1b and 1c). X-Galactosidase staining in TcfebLacZ/+ 
mice showed the same pattern of expression (Supplementary Fig. 1e). Together, our results 
show that TFEB expression is highly enriched in progenitor/ductal cells, while mature 
hepatocytes display lower TFEB levels, suggesting a possible role for TFEB in liver cell fate 
specification. 
TFEB influences liver cell differentiation in vitro 
To investigate whether TFEB plays a role in liver cell commitment, we generated 
CRISPR/Cas9 TcfebKO (TFEBKO)(Supplementary Fig. 2a) and TFEB overexpressing 
(TFEBOE) mouse HBs. To generate TFEBOE HBs, we isolated HBs from Tcfeb conditional 
overexpressing mice that carry Tcfeb-3xFlagfs/fs under the control of a strong CMV early 
enhancer/chicken beta-actin (CAG) promoter (Supplementary Fig. 2b)28,35. To induce Tcfeb 
overexpression, we infected HBs with an HDAd-BOS-CRE virus. HBs are bi-potent cells that 
can differentiate into hepatocytes or cholangiocytes in culture when plated on uncoated or 
matrigel coated plates, respectively38. Consistently, control HBs differentiated into 
hepatocytes forming hepatocyte clusters (Fig. 2a) and showed induction of the expression of 
hepatocyte-specific genes such as Alb, Hnf4α, AldoB and Otc, with concomitant reduction of 
the expression of the precursor markers Sox9, Sox4, Afp and Cd24 (Fig. 2b). Notably, HBs 
lacking TFEB showed significantly increased expression of the hepatocyte-specific markers 
and reduced Sox9 levels compared to controls, with no differences in the expression of the 
precursor markers Afp, Sox4 and Cd24 (Fig. 2b), suggesting that TFEB loss-of-function 
preferentially induces the hepatocyte differentiation program. On the contrary, TFEB 
overexpressing HBs did not completely differentiate into hepatocytes, as demonstrated by the 
smaller size of the hepatocyte-like aggregates (Fig. 2a), lower expression levels of 
hepatocyte-specific genes and higher levels of the precursor-specific markers (Fig. 2b), 
suggesting that TFEB overexpression prevents the hepatic differentiation of HBs, while 
maintaining precursor features. These results were confirmed by immunoblot and 
immunofluorescence analysis on HBs 3 days after hepatocytic differentiation (Fig. 2c and 2d).   
To confirm the defective differentiation program, we examined the effect of TFEB 
overexpression and depletion on the transcriptome of HBs 3 days after differentiation toward 
the hepatocytic lineage. Transcriptional profiles of TFEBKO and TFEBOE HBs confirmed the 
altered expression of hepatocyte- and progenitor/cholangiocyte- specific genes (Fig. 2e). 
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KEGG analysis on the differentially expressed genes showed upregulation of hepatocyte-
specific pathways, such as drug metabolism- cytochrome P450, fat digestion and absorption 
and cholesterol metabolism in TFEBKO HBs that were instead downregulated in TFEBOE HBs 
(Supplementary Tables 1 and 2). Moreover, Gene set enrichment analysis (GSEA) 
demonstrated that HNF4α targets (a master transcriptional regulator of hepatocyte 
differentiation) are enriched among up-regulated genes in TFEBKO HBs and show a reduced 
expression, despite not significant, in TFEBOE HBs (Supplementary Fig. 2c). We also 
examined the distribution of HBs in the three phases of the cell cycle (G1 vs S vs G2/M). 
TFEBKO HBs showed significant increase in the percentage of S phase cells compared to 
controls, suggesting that TFEB depletion induces S phase arrest in HBs (Fig. 2f). Interestingly, 
TFEB overexpression in HBs resulted in increased percentage of cells in G2/M phase 
compared with control cells with a concomitant reduction in S phase (Fig. 2f), suggesting 
increased proliferation.  
In contrast to the complete inhibition of hepatocyte specification, neither TFEB depletion nor 
overexpression impaired biliary differentiation of HBs. Indeed, TFEBKO and TFEBOE cells 
supported tubule formation (Supplementary Fig. 2d) and expressed biliary genes (i.e. Hif1α, 
Hnf6, Ggt1) after cholangiocytic differentiation despite the reduced or increased expression 
levels of both Sox9 and Afp, respectively (Supplementary Fig. 2e).  
Together these results indicate that TFEB plays a role in the lineage commitment of liver 
precursor cells. 
TFEB overexpression induces a progenitor/biliary phenotype in vivo 
To test whether TFEB overexpression alters cell differentiation from a progenitor state and 
impairs homeostasis of mature hepatocytes in vivo, we crossed the Tcfeb-3xFlagfs/fs mouse 
line (Supplementary Fig. 2b) with a transgenic line carrying Alb-Cre recombinase to obtain 
Tcfeb-3xFlagfs/fs;Alb-Cre mice (hereafter referred to as Tg). Albumin is expressed by the 
bipotential HB progenitors, thus enabling us to investigate the role of TFEB during liver cell 
specification. tdTomato expression and in situ hybridization analysis confirmed TFEB 
overexpression in hepatocytes and BECs at E18.5, P0 and P9 (Supplementary Fig. 3a and 
3b). Hepatoblast-specific expression of TFEB was assessed by qPCR analysis on liver 
extracts of Tg mice showing an approximately 10-fold increase of Tcfeb mRNA levels in E18.5, 
P0 and P9 livers and up to 65-fold in 3-month-old mice (Supplementary Fig. 3c), consistent 
with the progressive increase in Alb mRNA during liver specification39.   
To examine the effects of TFEB overexpression in vivo, we carried out microarray analysis at 
an early stage (P9) showing a total of 8,400 differentially expressed genes. KEGG analysis 
revealed that several up-regulated genes are involved in oxidative phosphorylation, 
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proteasome, cell cycle, Hippo signaling pathway and endocytosis, among others, while down-
regulated genes are mostly involved in hepatocyte-specific pathways, such as amino acid, 
cholesterol, and lipid metabolism, drug metabolism (P450), PPAR signaling pathway (Fig. 3a 
and Supplementary Table 3). Consistent with in vitro data, gene expression profile of Tg 
livers demonstrated a reduction in the expression of hepatocyte-specific genes and an 
increase in progenitor/cholangiocyte related genes compared with control livers (Fig. 3b and 
3c and Supplementary Table 4). Immunoblotting analysis confirmed the reduction of HNF4α 
and the increase of SOX9 protein levels in liver extracts from Tg mice at P9 (Fig. 3d). Similar 
results were obtained in primary hepatocytes isolated from 21-day-old Tg and control mice 
(Supplementary Fig. 4a and 4b). Interestingly, while no CK19+ cells were detected in control 
hepatocytes, we found HNF4α+/CK19+ Tg cells, suggesting a hybrid phenotype of Tg 
hepatocytes (Supplementary Fig. 4c). Indeed, immunostaining for the cholangiocyte marker 
CK19 in Tg livers from P0 mice showed CK19+ cells with hepatocyte-like morphology positive 
for the hepatocyte marker HNF4α mainly in the periportal area (Fig. 3e and Supplementary 
Fig. 5a). The concomitant positive signals for both a cholangiocyte and a hepatocyte marker 
suggest defective differentiation. At P9, Tg mice exhibited dilated bile ducts and ectopic 
tubules throughout the lobule (Fig. 3e and Supplementary Fig. 5a). Immunofluorescence 
analysis showed that most of the ductal CK19+ cells were positive for SOX9 (Supplementary 
Fig. 5b), as expected, but other cells scattered in the entire parenchyma were 
HNF4α+/SOX9+/CK19- in P0 and P9 livers (Fig 3e and Supplementary Fig 6a), suggesting 
that they were hepatocytes with bi-phenotypic features. In situ hybridization analysis 
confirmed that SOX9 was expressed in the entire liver in Tg mice compared to controls 
(Supplementary Fig. 6b).  
Together, these observations suggested that TFEB overexpression directs cell fate of HBs 
towards a progenitor/cholangiocyte lineage.  
 
Sox9 is a direct target of TFEB  
Our transcriptomic analysis in TFEBOE HBs and livers showed enrichment in several 
progenitor-specific genes, including Sox9. Sox9 overexpression is known to be sufficient to 
induce biliary genes and suppress differentiation into the hepatocyte lineage40. Therefore, we 
investigated whether Sox9 is a direct transcriptional target of TFEB and a mediator of TFEB 
effects on liver cell differentiation. We analyzed the promoter region of Sox9 gene and 
identified five putative TFEB target sites (i.e. the CLEAR sites)27 that were validated by 
chromatin immuno-precipitation (ChIP) analysis. Compared with a control sequence, the 
sequences closest to the Sox9 transcriptional start site (TSS) were significantly enriched in 
liver samples from Tg mice (Fig. 4a). The region containing CLEAR sites closest to the TSS 
was cloned into a luciferase reporter plasmid to evaluate its responsiveness to TFEB in HBs. 
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Overexpression of TFEB increased luciferase activity in HBs, whereas deletion of the CLEAR 
sites failed to induce transactivation (Fig. 4b). Taken together these data indicate that TFEB 
binds to the Sox9 promoter, identifying Sox9 as a direct transcriptional target of TFEB.  
To further validate our findings, we performed genetic interaction studies by crossing Tcfeb-
3xFlagfs/fs;Alb-Cre with Sox9f/f mice to generate double transgenic Tcfeb-3xFlagfs/fs;Alb-
Cre;Sox9f/+ mice (hereafter Tg;Sox9f/+). The expression of Sox9 was significantly reduced in 
livers from Tg;Sox9f/+compared with Tg mice (Fig. 4c and 4d). qPCR analysis on livers from 
Tg;Sox9f/+ at P9 showed higher expression levels of hepatocyte-specific markers (e.g. Alb, 
AldoB and Otc) and a reduction of cholangiocyte-markers (e.g. Krt7 and Krt19) compared with 
Tg mice (Fig. 4c). Interestingly, immunostaining analysis showed that Sox9 knockdown 
resulted in reduced number of CK19+ cells compared to Tg liver (Fig. 4e). These data suggest 
that SOX9 mediates, at least partially, the effects of TFEB on the determination of liver cell 
fate. 
 
TFEB depletion impairs LPC expansion upon liver injury and regeneration   
We then investigated the effects of TFEB deletion on liver cell differentiation in a previously 
described TFEB liver-specific conditional KO mouse line Alb-Cre;Tcfebf/f (TcfebLiKO)29. While 
immunofluorescence analysis did not reveal any significant cell differentiation defect in TFEB 
depleted livers compared to age-matched controls at P0 and 1 month (Supplementary Fig. 
7),  DDC-induced liver damage (Fig. 5a) in TcfebLiKO mice resulted in a  reduction in the 
expression of Sox9 and Krt19 during the recovery phase (Fig. 5b), which was confirmed by 
immunoblot analysis and immunostaining for SOX9 at 14 days after recovery (Fig. 5c and 
5d). These mice also showed a reduced ductular reaction as measured by CK19 
immunostaining (Fig. 5d). Interestingly, while control livers showed hybrid hepatocytes 
positive for both HNF4α and SOX9 around the portal vein as consequence of liver damage, 
as previously shown41, TcfebLiKO mice showed SOX9+ cells only in the portal area (Fig. 5d and 
5e) and a strong reduction of proliferating SOX9+ and CK19+ cells, indicating impaired LPC 
activation (Fig. 5f and 5g). No main differences were observed in weight recovery after injury 
in the two genotypes (Supplementary Fig. 8a), while an increase in serum markers of liver 
damage (e.g. bilirubin and AST) was detected in TcfebLiKO mice compared to control mice 
(Supplementary Fig. 8b). These data suggest that liver cell differentiation after injury requires 
TFEB induction. Consistently, we found that TFEB translocates from the cytoplasm to the 
nucleus 7 days after recovery from DDC-induced liver injury (Supplementary Fig. 8c), a time 
point during which we detected a reduction in mTOR activity, as measured by detecting the 
phosphorylation of the mTOR substrate 4EBP1 (Supplementary Fig. 8d).   
 
		 8	
TFEB overexpression in regenerating adult liver subverts cell identity 
The effects of TFEB overexpression in the progenitor/cholangiocyte compartment were 
investigated by crossing the Tcfeb-3xFlagfs/fs;R26RLSLtdTomato mice with an inducible 
Krt19CreERT mouse line that labels the biliary epithelium with a 40% recombination efficiency 
(Fig. 6a and 6b)11. Four-weeks after tamoxifen injection, tdTom expression was observed only 
in biliary ducts and in small periportal ductules (Fig. 6a). Based on the results obtained in Alb-
Cre mice, we hypothesized that TFEB overexpression would expand the CK19+ population in 
the periportal area by generating a ductal reaction. Indeed, we observed an increase in 
CK19+/tdTom+ cells in Tg mice compared to controls (Fig. 6b), hyperplasia of the bile ducts 
and a population of cells growing within the ductal epithelium and forming multilayered 
structures (Fig. 6a). In addition, some of the CK19+/tdTom+ cells appeared with a rounded 
morphology, compared to the cuboidal biliary epithelium observed in control mice, with a 
migrating phenotype that mimics a ductular reaction (Fig. 6a). This phenotype strongly 
resembles the one observed in YAP-overexpressing biliary cells42.  
Subsequently, to stimulate a progenitor/biliary-derived liver regenerative response, we 
induced chronic liver damage by feeding mice with a 0.1% 3,5-diethoxycarbonyl-1,4-
dihydrocollidine (DDC)-containing diet for 3 weeks and then switch to a normal diet for 14 
days, a protocol causing transient LPC activation (Fig. 6c) 6. Interestingly, while control mice 
showed tdTom+ cholangiocytes in the portal area and the expected ductular reaction as shown 
by tdTom, CK19 and SOX9 immunostaining (Fig. 6d), most of the CK19+ and SOX9+ 
cholangiocytes were tdTom+ in Tg mice, suggesting increased proliferation of the tdTom+ cells 
upon TFEB overexpression, as also confirmed by BrdU analysis (Fig. 6d). Notably, these mice 
recapitulate the same phenotype observed in the Alb-Cre;Tcfeb-3xFlagfs/fs mice.  
To overexpress TFEB specifically in the hepatocytes, we injected Tcfeb-
3xFlagfs/fs;R26RLSLtdTomato mice with a CRE-expressing adeno-associated virus (AAV8-
TBG-CRE). As expected, AAV8 injection induced CRE expression in 99% of the hepatocytes 
and no expression in the biliary cells as demonstrated by tdTom staining (Fig 7a)6. These 
mice showed 20-fold increase of Tcfeb expression at 4-weeks after injection (Fig 7b), but no 
alteration in cell identity compared to controls (Fig 7c). These results suggest that TFEB 
overexpression in differentiated adult hepatocytes is not sufficient to induce their conversion 
to cholangiocytes.  
To evaluate whether TFEB overexpression in hepatocytes alters cell identity upon liver injury, 
we fed Tcfeb-3xFlagfs/fs;R26RLSLtdTomato mice injected with AAV8-TBG-CTRL or AAV8-TBG-
CRE with the DDC-containing diet. We first used a protocol of acute injury by feeding mice a 
DDC-containing diet for 5 days and switching to a normal diet for 14 days (Fig 7d). 
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Interestingly, CRE-injected mice showed tdTom+ hepatocytes positive for SOX9 and CK19, 
strongly suggesting a conversion of TFEBOE cells in progenitor/cholangiocyte-like cells upon 
liver damage (Fig 7e). Notably, the chronic exposure to DDC-containing food for 3 weeks 
following by 14 days of recovery resulted in liver tumors in CRE-injected mice (Fig 7f and 7g). 
Histological analysis showed that most of the CK19+/SOX9+ cells were tdTom+, and that some 
tdTom+ hepatocytes also expressed SOX9 (Fig 7h), confirming that TFEB overexpression in 
hepatocytes leads to trans-differentiation in progenitor/cholangiocytes in conditions of liver 
damage when cells are more prone to proliferation and trans-differentiation. 
Together our data strongly confirm that TFEB overexpression in progenitors/cholangiocytes is 
able to influence proliferation and differentiation.  
Liver cysts, cholestasis and cholangiocarcinoma-like phenotype in TFEBOE mice  
We then analyzed the phenotypic consequence of the altered cell differentiation associated 
with TFEB overexpression in the liver. Tg mice exhibited significant hepatocellular 
derangement as shown by an increase of liver damage markers, as well as a significant 
increase in both total bilirubin and direct bilirubin at 15 days and 3 months (Supplementary 
Table 5) consistent with cholestasis. Serum bile acid and cholesterol levels were also 
increased in Tg mice compared to controls (Supplementary Table 5). Analysis of three-
dimensional structure of the biliary system in adult liver, performed by retrograde injection of 
ink in the biliary tree in 2-month-old mice, confirmed a defect in bile duct development (Fig. 
8a). Indeed, we observed reduced density of branches arising from major branches and 
abnormal major branches in appearance consistent with partial obstruction of bile flow, 
correlating with increased bilirubin and ALT levels. Furthermore, Tg mice showed a 
progressive increase in liver mass relative to total body mass with a 2, 4 and 10-fold increase 
at 2 weeks, 2 months, and 5 months of age, respectively (Fig. 8b and 8c). At 3 months, TFEB 
overexpression was detected in the entire parenchyma and in particular in the dilated ducts 
as demonstrated by immunohistochemistry and in situ hybridization analysis (Fig. 8d). Livers 
from Tg mice displayed variable degrees of hyperplasia of bile ducts, which were increased in 
size and number, and an altered morphology of epithelial cells. In addition, they showed 
multifocal biliary cystic hyperplasia with cysts lined by flattened epithelium at 3 months of age 
(Fig. 8e). Densely packed cholangiocytes, as revealed by CK19 immunostaining, associated 
with increased fibrosis revealed by Sirius red staining, were also detected suggesting the 
presence of a neoplasms of the bile ducts. All of these phenotypic features are consistent with 
the presence of a cholangiocarcinoma (CCA)-like phenotype. Livers from 6-month-old Tg mice 
showed multiple cysts replacing most of the hepatic parenchyma. At this age mice began to 
die or needed to be euthanized due to poor health status. Increased liver mass in Tg mice 
was associated with a higher proliferation index compared to control mice, as shown by 
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increased Ki67 staining (Fig. 8e). A similar, albeit milder and with later onset, phenotype was 
observed in a different transgenic mouse line in which Tcfeb is overexpressed at lower levels 
(2.5-fold increase) suggesting a dose- and time-dependent effect of TFEB overexpression 
(Supplementary Fig. 9a-9d).  
These data are consistent with a pro-cholangiocytic function of TFEB and suggest that TFEB 
induction may be involved in the pathogenesis of cholangiocarcinoma.   
Discussion 
Recent studies have identified an important role for MiT-TFE transcription factors (TFs) in the 
regulation of basic cellular processes, such as lysosome, autophagosome and melanosome 
biogenesis27,28,43,44. These TFs control organismal adaptation to environmental cues, such as 
nutrient availability, physical exercise and infections32,33,37,45-49. While some studies reported 
the involvement of MiT-TFE genes in cell differentiation, the precise role that these TFs play 
in cell specification and in embryonic development has remained elusive. TFEB full KO mice 
die at E10 due to a placental vascularization defect, indicating that embryonic development 
requires TFEB mediated transcriptional control26. In addition, previous studies showed that 
MITF and TFEB are involved in the differentiation processes of melanocytes and osteoclasts, 
respectively50. A recent study also reported a role for TFEB in the activation and response to 
growth factor in quiescent neuronal stem cells (qNSCs)51. Furthermore, TFE3, another 
member of the MiT family, was shown to be involved in stem-cell commitment by enabling 
ESCs to withstand differentiation condition52. In the present study, we reveal a novel role for 
TFEB in liver cell differentiation during development and in the regenerative response to injury. 
We found that TFEB expression levels increase over time during liver specification. Moreover, 
we observed differences in the levels of TFEB expression between pericentral vs periportal 
area suggesting that different levels of TFEB could determine different progenitor cell fates. 
Indeed, our data show that TFEB mainly specify the cholangiocyte lineage. This is also 
supported by the finding that TFEB overexpression in hepatoblasts dictates a 
progenitor/cholangiocytic fate resulting in a rapid replacement of the entire liver by biliary 
structures. In this regard, it will be interesting to determine the mechanisms that allow the 
differential expression of TFEB in specific subsets of cells.  
Hepatocyte identity is defined by the expression of a core group of transcription factors 
primarily driven by the CCAAT/enhancer binding protein alpha (C/EBPα)53, a key hepatic 
transcription factor that also controls the expression of genes involved in ammonia 
detoxification and glucose and lipid homeostasis54. Another key regulator of cell identity in the 
liver is SOX9, a transcription factor that drives bile duct morphogenesis and is recognized as 
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a specific marker of precursors and biliary cells in the developing liver55. Remarkably, C/EBPα 
and SOX9 form a mutually antagonistic system controlling the hepatocyte versus biliary fate 
during normal liver homeostasis and regeneration40. Our in vitro and in vivo studies indicate 
that TFEB directly controls the expression of Sox9 during progenitor/ductal specification and 
after liver injury. Indeed, our epistatic analysis using Sox9-deficient mice provides evidence 
that TFEB-mediated regulation of SOX9 is required for proper differentiation of bi-potential 
progenitors, although additional mechanisms downstream of TFEB are likely to play a role.  
Consistent with a role of TFEB in the determination of liver cell fate, we found that mice 
overexpressing TFEB in the liver showed increased proliferation of progenitor cells, expansion 
of immature BECs and inhibition of the hepatocyte lineage. An opposite phenotype was 
observed in Tcfeb-depleted HBs and liver, which appeared more prone to differentiation into 
the hepatocyte lineage (Supplementary Fig 10).  
Although liver parenchymal cells turn over slowly, the liver displays high regenerative capacity, 
capable of restoring 70% tissue loss within a few weeks56. This ability is vital for the liver to 
maintain constant mass. The population of liver cell responding to injury may differ depending 
on the site, type and the duration of injury. HybHPs are located in the periportal area and 
express progenitor markers, such as Sox9, and hepatocyte markers, such as Hnf4α. This 
population of specialized hepatocytes are able to reconstitute the liver mass after various 
chronic injuries21. Sox9+/Hnf4α+ bi-phenotypic hepatocytes able to differentiate in either 
hepatocytes or cholangiocytes have been also identified in DDC-injured livers41. These cells 
represent the intermediate status of lineage conversion during liver regeneration. We found 
that conditional deletion of TFEB in the liver results in impaired LPCs activation. Moreover, we 
demonstrated that TFEB depleted hepatocytes fail to express Sox9 after liver damage, thus 
suggesting that TFEB-dependent Sox9 induction plays an important role in liver homeostasis 
in response to injury. This observation is in line with the known role of TFEB in the cellular 
adaptation to environmental cues such as various types of stress conditions33,47.  
It is known that overexpression of endogenous MiT-TFE transcription factors, as a result of 
chromosomal abnormalities such as translocations or gene amplifications, can drive 
tumorigenesis in renal cell carcinoma and melanoma34,35,37,57 and to support cancer growth in 
pancreatic cancer35-37. However, a specific role for TFEB in cell differentiation, proliferation 
and neoplastic transformation in the liver has never been demonstrated. Here, we show that 
Albumin-CRE-driven TFEB overexpression in the liver of transgenic mice results in a severe 
phenotype characterized by a progressive increase in liver mass, hyperplasia of bile ducts, 
altered biliary tree structure, multifocal biliary cystic hyperplasia and fibrosis. Cholestasis, bile 
duct proliferation and cystic alterations rapidly progress ultimately leading to biliary tumor with 
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features resembling cholangiocarcinoma (CCA). Previous studies showed that SOX9 is highly 
up-regulated in many premalignant lesions and in tumor tissues and plays a role in tumor 
development58-60. Our results suggest that TFEB-mediated up-regulation of Sox9 expression 
plays a role in liver cancer development by inducing progenitor cell proliferation.  
In conclusion, our study reveals an important role for TFEB in liver development and cell fate 
under physiological and pathological conditions. Further studies of this mechanism may lead 
to the identification of novel therapeutic targets for the modulation of liver regeneration after 
injury.  
Methods 
Mouse experiments. All mice used in experiments were males and were maintained on a 
C57BL/6 strain background. All experiments were approved by the Baylor College of Medicine 
Institutional Animal Care and Use Committee (IACUC) and conform to the legal mandates and 
federal guidelines for the care and maintenance of laboratory animals.  
TcfebLacZ/LacZ, Tcfebflox/flox and Tcfeb-3xFlagfs/fs transgenic mouse line generation has been 
previously described28,29. Wild-type, Sox9flox/flox, R26RLSLtdTomato, Albumin-Cre and 
Krt19CreERT mouse lines were obtained from the Jackson laboratory (Bar, Harbor, ME).  
The Krt19CreERT was induced by three individual intraperitoneal injections of tamoxifen at a 
dose of 4 mg. Krt19CreERT mice received 2 weeks of normal diet after the last tamoxifen injection 
before starting an injury diet regime. 
To induce liver injury, mice were given 0.1% DDC food (Custom Animal Diet, Bangor, PA) as 
indicated in the text. After injury, mice were given normal chow and drinking water.    
 
Cell culture. Hepatoblasts (HBs) were prepared from control and Tcfeb-3xFlagfs/fs mice at 
embryonic day 13.5 and immortalized by plating at clonal density61. HBs were maintained in 
HB media (RPMI) (Thermo Fisher Scientific, Wilmington, DE) containing 10% FBS, 1% 
penicillin-streptomycin, 50 ng/ml epidermal growth factor, 30 ng/ml insulin-like growth factor II 
(PeproTech, Rocky Hill, NJ), 10 μg/ml insulin (Roche Diagnostics, Indianapolis, IN) on plates 
coated with rat tail collagen (BD Bioscience, San Jose, CA) in a humidified atmosphere with 
5% CO2 at 37°C. Cells were infected with HDAd-BOS-CRE or HDAd-CMV-LacZ vectors 
(previously described62,63) and then cultured for the specific assay. For hepatocyte 
differentiation, HBs were cultured on uncoated tissue culture dishes in HB medium for up to 5 
days. For bile duct differentiation, 6 cm tissue culture dishes were coated with 0.5 ml 
Basement Membrane Matrix (BD Bioscience, San Jose, CA) and allowed to set for 1 h. HBs 
in HB cell media supplemented with 100 ng/ml recombinant mouse hepatocyte growth factor 
(HGF) (R&D System, Minneapolis, MN) were then added to the plate. Tubule formation was 
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monitored at 24 hours, 3 days and 10 days.  
Primary mouse hepatocytes were isolated using a two-step perfusion technique as previously 
described64. Briefly, WT or transgenic mouse liver was perfused with collagenase (C5138, 
Sigma-Aldrich, Saint Louis, MO) and parenchymal cells were squeezed out from the liver. The 
hepatocyte suspension was further purified using a 40% of Percoll gradient (P4937, Sigma-
Aldrich, Saint Louis, MO), washed with Hepatocyte Wash Medium (17004-024; Thermo Fisher 
Scientific) and plated at an appropriate cell density. Cells were harvested for analysis after 24 
hours.  
 
Generation of TcfebKO hepatoblasts through CRISPR-Cas9. Two sgRNAs targeting 
adjacent regions of Tcfeb exon 3 were designed and synthetized as previously described65,66 
with minimal modification. Briefly, forward primers containing the T7 promoter sequence, the 
proto-spacer sequence and the sgRNA scaffold overlap sequence were designed through 
CRISPRscan67. Full-lenght sgRNA scaffold was obtained through an overlap PCR with the 
universal scaffold reverse primer.  Tfeb sgRNA 1 Forward: 
taatacgactcactataGGGTATCTGTCTGAGACCTAgttttagagctagaaatagc 
Tfeb sgRNA 2 Forward: 
taatacgactcactataGGCAGGCTTCGGGGAACCTTgttttagagctagaaatagc 
Universal scaffold Reverse: 
gttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgct 
PCR products were used for in vitro transcription (IVT). IVT was performed using the HiScribe 
T7 High Yield RNA Synthesis kit (NEB) following manufacturer instructions. Purified sgRNAs 
were pre-complexed with spCas9 protein (IDT). Finally, sgRNA-Cas9 ribonucleoproteins 
(RNP) containing the two sgRNAs were simultaneously transfected into primary mouse 
Hepatoblasts using the NEON Transfection System (ThermoFisher) and the following 
electroporation conditions: Buffer R, 1400 V, 10 ms, 3 pulses. Deletion efficiency was 
assessed through PCR using the following primers: Tcfeb Forward: 
GTCCACTTCCAGTCGCCC; Tcfeb Reverse: AGGCTAGAGGCCCATAAAGAA.  
 
Flow cytometry and cell cycle analysis. HBs were cultured on collagen-coated plates, 
harvested with trypsin-EDTA (Thermo Fisher Scientific, Wilmington, DE), and washed in PBS. 
For cell cycle analysis, cells were fixed in 1 ml cold 70% ethanol for 30 minutes on ice and 
then centrifuged for 5 minutes at high speed. The pellet was washed twice in PBS and treated 
with RNAseA (Life Technologies, Carlsbad, CA). Propidium Iodide (PI) solution was added to 
the cells and the mixture incubated for 10 minutes at room temperature. Cell debris and dead 
cells were excluded from FSC-A/SSC-A dot-plots (Supplementary Figure 11a). DNA content 
and relative cell cycle phases was determined based on PI relative fluorescence levels on 
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singlets (Supplementary Figure 11b). FACS experiments were performed using an LSRII 
cytometer (BD Bioscience, San Jose, CA Bioscience, San Jose, CA). Data were analyzed 
using FACSDiva (BD Bioscience, San Jose, CA) and Flow-Jo (Flow-Jo, LLC, Ashland, OR) 
software. Cell cycle phases were quantified using the Flow-Jo Cell Cycle platform (univariate). 
In all experiments at least 10000 events were acquired.  
 
RNA extraction and quantitative RT-PCR. Total RNA was extracted in TRIzol reagent (Life 
Technologies, Carlsbad, CA) using RNeasy kit (Qiagen, Hilden, Germany). RNA was reverse 
transcribed using a first strand complementary deoxyribonucleic acid kit with random primers 
according to the manufacturer’s protocol (Applied Biosystems). The RT-PCR reactions were 
performed using the CFX96 Real Time System (Bio-Rad, Hercules, CA). The PCR reaction 
was performed using iTaq SYBR Green Supermix (Bio-Rad, Hercules, CA) with the following 
thermocycler conditions: pre-heating, 5 min at 95°C; cycling, 40 cycles of 15 s at 95°C, 15 s 
at 60°C and 25 s at 72°C. Results were expressed in terms of cycle threshold(Ct). The Ct 
values were averaged for each duplicate. The ß2-microglobulin, Ribosomal protein S16 or 
Cyclophilin genes were used as endogenous controls (reference markers). Differences 
between the mean Ct values of the tested genes and those of the reference gene were 
calculated as ∆Ctgene=Ctgene-Ctreference. Relative fold increase in expression level was 
determined as 2-∆∆Ct. Primers used for RT-PCR are listed in Supplementary Table 6  
 
Western blotting. Liver and cells samples were homogenized in RIPA buffer (50mM Tris–
HCl pH 7.4, 150mM NaCl, 1% Triton X-100, 1mM EDTA pH 8.0, 0.1% SDS) containing 
complete protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). Samples were 
incubated for 20 minutes at 4°C and centrifuged at 16,000 g for 10 minutes. The pellet was 
discarded, and cell lysates were used for Western blot analysis. Ten to twenty micrograms of 
liver protein were run on a 4-20% SDS-PAGE polyacrylamide gel by electrophoresis. After 
transfer to a PVDF membrane, the blots were blocked in TBS-Tween 20 containing 5% non-
fat milk for 1 hour at room temperature, then exposed to primary antibody was applied 
overnight at 4°C. Anti-rabbit IgG or anti-mouse IgG conjugated with horseradish peroxidase 
(GE Healthcare, Little Chalfont, UK) and ECL (Pierce, Thermo Fisher Scientific, Wilmington, 
DE) was used for detection. Antibodies used for immuno-blots are listed in Supplementary 
Table 7.  
 
Cellular fractionation. Enriched nuclear and cytosolic cellular subfractions were isolated by 
differential centrifugation, as previously described68. Briefly, the liver was minced on ice and 
homogenized using a Teflon pestle and mortar and suspended in mitochondrial isolation buffer 
(MIB; 250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM 
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EGTA) supplemented with protease and phosphatase inhibitor cocktails (Complete and 
PhosSTOP Roche, Roche Diagnostics, Basel, Switzerland). The homogenates were then 
centrifuged at 1,000 g for 10 min at 4°C to pellet the nuclei while mitochondrial and cytosolic 
fractions were contained within the supernatant. The supernatant fraction was re-centrifuged 
twice at 16,000 g for 20 min at 4°C to pellet the mitochondria and supernatant containing 
cytosolic subfraction was collected. Pellets containing nuclei were re-suspended in nuclear 
lysis buffer (1.5 mM MgCl2, 0.2 mM EDTA, 20 mM HEPES, 0.5 M NaCl, 20% glycerol, 1% 
Triton X-100), incubated on ice for 30 min, and then sonicated 3 Å~ 10 s followed by a final 
centrifugation step of 15 min at 16,000 g. The supernatant was collected to obtain the enriched 
nuclear fraction. Fraction purity was determined by Western blot analysis. 
 
In situ hybridization. Livers from P9 and 3-month-old WT and Tg mice were collected and 
frozen without prior fixation in OCT cryoprotection media. Tissue was cut into 25-µm sections, 
mounted on slides with ProlongGold with DAPI (Life Technologies, Carlsbad, CA) and used 
for RNA in situ hybridization (ISH). We utilized the previously described method69 but modified 
the development of the signal by using a Cy3-labeled tyramide instead of the biotin-labeled 
tyramide. Tcfeb-probe-F1 5’-GCGGCAGAAGAAAGACAATC-3’ and Tcfeb-probe-R1 5’-
AGGTGATGGAACGGAGACTG-3’ were used to amplify 1300 bp from mouse liver cDNA and 
cloned into pGEM_T Easy vector (Promega, Madison, MI). This template was used to 
generate a DIG-labeled mRNA probe using in vitro transcription reagents from Roche (Roche 
Diagnostics, Indianapolis, IN). 
 
Liver staining. Livers were dissected, fixed with buffered 10% formalin overnight at 4°C and 
stored in 70% ethanol, embedded into paraffin blocks and cut into 6-µm sections. For Sirius 
red staining the sections were rehydrated and stained for 1 hour in picro-sirius red solution 
(0.1% Sirius red in a saturated aqueous solution of picric acid) (Sigma-Aldrich, Saint Louis, 
MO). After two changes of acidified water (5ml glacial acetic acid in 1 L of water), the sections 
were dehydrated in three washes of 100% ethanol, cleared in xylene, and mounted on a 
resinous medium. X-Gal and H&E stainings were performed following the IHC World protocol. 
For immuno-staining, the sections were rehydrated to PBS pH 7.4 and permeabilized with 
0.2% Triton in PBS. Heat Induced Epitope Retrieval using the citrate buffer method (pH 6.0) 
was performed to retrieve the antigen sites. The sections were then incubated for 1 hour at 
room temperature with blocking solution (3% BSA, 5% donkey serum, 20mM MgCl2, 0.3% 
Tween 20 in PBS pH 7.4). For co-stainings, primary antibodies were incubated overnight at 
4°C. Secondary antibodies made in donkey were: AlexaFluor-488 anti-rabbit and AlexaFluor-
594 anti-mouse (Life Technologies, Carlsbad, CA). Slides were mounted on ProlongGold with 
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DAPI (Life Technologies, Carlsbad, CA). For IHC, the Vectastain ABC kit and DAB (Vector 
Laboratories, Burlingame, CA) were used following the manufacturer’s instructions. Sections 
were counterstained using Mayer’s hematoxylin (Electron Microscopy Sciences, Hatfield, PA). 
For BrdU staining, 2 mg of BrdU (BD Bioscience) diluted in PBS 1x was injected by 
intraperitoneal injection 4 hours before tissue collection. Livers were dissected, fixed with 
buffered 10% formalin overnight at 4°C and embedded into OCT blocks and cut into 10-µm 
sections. BrdU signal was revealed by using a rat anti-BrdU antibody. Stained liver sections 
were examined under a Zeiss Axiocam MR microscope. For staining quantification, Image J 
Software (NIH) was used to calculate the percent area positively stained in five random low 
power views. 
 
Gene expression analysis. Total RNA from HBs 3 days after hepatocytic differentiation was 
quantified using the Qubit 2.0 fluorimetric Assay (Thermo Fisher Scientific). Libraries were 
prepared from 100ng of total RNA using the QuantSeq 3' mRNA-Seq Library Prep Kit FWD 
for Illumina (Lexogen GmbH). Quality of libraries was assessed by using screen tape High 
sensitivity DNA D1000 (Agilent Technologies). Libraries were sequenced on a NovaSeq 6000 
sequencing system using an S1, 100 cycles flow cell (Illumina Inc.). Sequence reads were 
trimmed using bbduk software (bbmap suite 37.31) to remove adapter sequences, poly-A tails 
and low-quality end bases (regions with average quality below 6). Alignment was performed 
with STAR 2.6.0a70 on mm10 reference assembly. The expression levels of genes were 
determined with htseq-count 0.9.171 by using mm10 Ensembl assembly (release 90). We have 
filtered out all genes having < 1 cpm in less than 2 samples.  Differential expression analysis 
was performed using edgeR72. 
Microarray analysis was performed on liver from P9 mice of each of the two genotypes (n=3 
per group). All samples were processed on Affymetrix Mouse 430A 2.0 arrays using GeneChip 
3’-IVT Plus and Hybridization Wash and Stain kits by means of Affymetrix standard protocols. 
Raw intensity values of the 6 arrays were processed and normalized by Robust Multi-Array 
Average Method73 using the Bioconductor R package Affy74. The data have been deposited in 
NCBIs Gene Expression Omnibus75 (GEO) and are accessible through GEO Series accession 
number GSE35015.  
Enrichment analyses of KEGG pathways on differentially expressed genes were performed 
using the Bioconductor R package clusterProfiler76 (FDR <= 0.05). Gene set enrichment 
analysis (GSEA) was run on HNF4α targets downloaded from the Molecular Signatures 
Database (MSigDB)77.   
 
		 17	
Promoter analysis. The analysis of TFEB binding sites was performed using the CLEAR 
matrix78 and the matchPWM algorithm79 implemented in the Biostrings package. Putative 
binding sites were filtered with threshold of significance set at 0.8. 
 
ChIP. ChIP was performed using livers of 2-month-old Alb-Cre;Tcfeb-3xFlag and control mice 
as previously described33. Primers used for RT-PCR are listed in Supplementary Table 8. 
 
Luciferase assay. The Sox9 promoter was amplified from mouse genomic DNA and cloned 
into the pGL4 plasmid (Promega, Madison, MI). A quick-change site directed mutagenesis kit 
(Agilent, Santa Clara, CA) was used for the mutagenesis of CLEAR sites in the Sox9 promoter. 
Primers used for mutagenesis are listed in Supplementary Table 9. Control HBs and HBs 
overexpressing Tcfeb were transfected with the Sox9 promoter-reporter luciferase construct 
and pRL-CMV (Promega, Madison, MI). Cells were harvested 24 hours after transfection and 
subjected to luminescence detection by dual luciferase assay using the Dual-Luciferase 
Reporter Assay system (Promega, Madison, MI). A Turner Designs Luminometer (DLReady) 
(Promega, Madison, MI) was used to measure luminescence normalized against Renilla 
luciferase activity. 
 
Biliary tree casting. Two-month-old mice were euthanized with isoflurane (Vedco Saint 
Joseph MO). Ink (Hyatt’s) was injected into the common bile duct using a 30-gauge needle. 
The entire liver was removed, formalin-fixed and clarified in a 1:2 solution of benzyl alcohol 
and benzyl benzoate. 
 
Blood chemistry analysis. Blood was collected from the retro-orbital plexus under isoflurane 
(Vedco Saint Joseph MO) anaesthesia. Serum was frozen at -20°C or used immediately after 
collection. Total Bile Acids (TBA) Enzymatic Cycling Assay Kit was obtained from BQKITS 
(San Diego, CA). 
 
Vector production and injections. pAAV-TBG-GFP-pA (GFP) was obtained from Thomas 
Vallim (University of California, Los Angeles). pAAV-TBG-PI-Cre-rBG (Cre Recombinase) and 
plasmids required for AAV packaging, adenoviral helper plasmid pAdDeltaF6 (PL-F-PVADF6) 
and AAV8 packaging plasmid pAAV2/8 (PL-T-PV0007) were obtained from the University of 
Pennsylvania Vector Core.  AAV were generated as previously described with some 
modifications80,81. Each AAV transgene construct was co-transfected with the packaging 
constructs into 293T cells (ATCC, CRL-3216) using polyethylenimine (PEI). Cell pellets were 
harvested and purified using a single cesium chloride density gradient centrifugation. 
Fractions containing AAV vector genomes were pooled and then dialyzed against PBS using 
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a 100kD Spectra-Por® Float-A-Lyzer® G2 dialysis device (Spectrum Labs, G235059) to 
remove the cesium chloride. Purified AAV were concentrated using a Sartorius™ Vivaspin™ 
Turbo 4 Ultrafiltration Unit (VS04T42) and stored at -80°C until use. AAV titers were calculated 
after DNase digestion using qPCR standard method. Primers used for titer are included in 
Supplementary table 10. Viruses were administered by retro-orbital injection at the dose of 
2x1011 genome copies/mouse. 
 
Statistical analyses. Data are expressed as averages ± standard error. Statistical 
significance was computed using Student’s 2-tail t-test. A p-value<0.05 is considered 
statistically significant.  
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Figure 1: TFEB expression is enriched in ductal/progenitor cells.  
(a) Immunohistochemistry analysis of TFEB in wild-type (WT) liver at the indicated stages 
showing prominent signaling in bile ductules. Arrows indicate ductal cells. PV=portal vein. 
Scale bar 20 μm. (b,c) Representative immunofluorescence stains for TFEB/HNF4α (b) and 
TFEB/SOX9 (c) showing TFEB levels in the central (CV) and in the portal (PV) vein area. 
Scale bar 20 μm.         
 
Figure 2: TFEB influences hepatoblast differentiation in vitro.  
(a) Hepatocyte sphere formation of HBs of the indicated genotypes 3 days after differentiation. 
(b) mRNA levels of the indicated genes were quantified by quantitative RT-PCR of total RNA 
isolated from control (CTRL), TFEB overexpressing (TFEBOE) and TFEB depleted (TFEBKO) 
HBs undifferentiated (collagen coated plates) or after 5 days of hepatocyte differentiation 
(uncoated plates). Values are indicated as mean ± SEM of n=3 and expressed as fold 
difference compared with CTRL undifferentiated HBs. (c) Immunoblotting analysis and relative 
quantification of the precursor/cholangiocyte marker SOX9 and the hepatocyte marker HNF4α 
in TFEBKO and TFEBOE HBs after 5 days of hepatocytic differentiation. (d) Immunostaining for 
the indicated markers on TFEBKO and TFEBOE HBs 5 days after hepatocytic differentiation. 
Scale bar 5 μm. (e) Gene expression profiling of hepatocyte and biliary genes of differentiated 
HBs of the indicated genotypes. (f) Flow cytometry analysis of the cell cycle distribution of 
undifferentiated CTRL, TFEBKO and TFEBOE HBs and relative quantification (n=3). Data are 
represented as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 two-tailed Student’s t-test. 
 
Figure 3: TFEB overexpression inhibits hepatocyte differentiation in vivo.  
(a) KEGG pathways enriched in upregulated and downregulated genes of P9 liver 
overexpressing TFEB compared to CTRL. (b) Heat map showing the relative fold change of 
hepatocyte and biliary genes. (c) RT-PCR analysis of hepatocyte- and cholangiocyte- specific 
markers in liver isolated from P0 and P9 mice (n=3). The dashed line represents gene 
expression levels in CTRL liver. Data are represented as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01 
two-tailed Student’s t-test. (d) Immunoblotting analysis of TFEB, HNF4α and SOX9 in liver 
extracts from mice at P9. Actin was used as loading control. (e) Left panel: Representative 
images of liver sections from P0 and P9 mice stained for CK19. Scale bar 50 μm. Right panels: 
triple immunostaining for HNF4α (red), SOX9 (green) and CK19 (white) in liver sections from 
P0 and P9 mice of the indicated genotype showing the hybrid characteristics of hepatocytes 
and cholangiocytes in Tg mice. Note cells expressing SOX9 and CK19 (box1), SOX9 and 
HNF4α (box2) or SOX9/HNF4α/CK19 (box3). Scale bar 20 μm.   
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Figure 4: TFEB directly controls Sox9 expression. 
(a) ChIP analysis of TFEB binding to the Sox9 promoter in Tg livers. CLEAR sites in the 
promoter region of Sox9 are indicated by red squares. Bar graphs show the amount of 
immuno-precipitated DNA as detected by RT-PCR analysis (n=2 independent experiments). 
Values were normalized to the input and plotted as relative enrichment over the control 
sequence. (b) Luciferase expression upon TFEB overexpression was measured in HBs 
infected with HDAd-LacZ (CTRL) or HDAd-CRE expressing viruses (TFEBOE) for 24 hours 
and transfected with wild type or mutated Sox9-promoter luciferase reporter plasmids (n=3). 
Deletion of the CLEAR sites resulted in reduced luciferase transactivation. (c) RT-PCR 
expression analysis of hepatocyte- and cholangiocyte- specific markers in livers isolated from 
P9 mice for the indicated genotypes (n=3). (d) Representative immunoblot for SOX9 in liver 
of the indicated genotypes and relative quantification. (e) CK19 immunostaining of liver 
sections from P9 mice of the indicated genotypes. Scale bar 50 μm. Data are represented as 
mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 two-tailed Student’s t-test.   
 
Figure 5: TFEB depletion impairs ductular reaction and cell proliferation after liver 
injury. 
(a) Experimental strategy for liver injury protocol for TFEBLiKO mice. (b,c) Expression levels of 
Sox9 and Krt19 mRNA (n=5) at different time points (b) and immunoblotting with relative 
quantification (n=4) (c) of livers isolated from TFEBf/f and TFEBLiKO mice 14 days after 
discontinuation of DDC food. Values are expressed as fold difference relative to TFEBf/f mice. 
(d) SOX9 and CK19 immuno-fluorescence with relative quantifications (n=3) of liver isolated 
from TFEBf/f and TFEBLiKO mice 14 days after recovery and relative quantifications. Scale bar 
50 μm. (e) HNF4α/SOX9 dual staining of liver sections from TFEBf/f and TFEBLiKO mice. Scale 
bar 5 μm. (f,g) Quantification of BrdU+ cells (f) and representative images (g). Scale bar 50 
μm. Data are represented as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01 two-tailed Student’s t-test. 
 
Figure 6: TFEB overexpression in progenitor/cholangiocytes gives rise to ectopic 
ductal structures.  
(a) Representative images of CK19/tdTom dual immunofluorescence of CTRL and TFEBOE 
liver four-weeks after tamoxifen injection. Scale bar 50 μm. (b) Quantification of CK19+ biliary 
epithelial cells that were tdTom+ (n=3 mice analyzed, 5 sections per mouse). Data are 
represented as mean ± SEM. **p ≤ 0.01 two-tailed Student’s t-test. (c) Experimental strategy 
to lineage trace biliary epithelial cells on a background of liver injury. (d) tdTom/HNF4α, 
tdTom/SOX9 and tdTom/CK19 Immunofluorescent images at 14 days after DDC diet. Scale 
bar 50 μm.   
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Figure 7: TFEB-overexpressing hepatocytes dedifferentiate in 
progenitor/cholangiocyte-like cells upon liver injury. 
(a) tdTom/CK19 and tdTom/HNF4α immunofluorescence in AAV8-TBG-CRE-treated livers 4 
weeks after injection. CRE-treated HNF4α+ hepatocytes are tdTom+ in contrast to CK19+ 
ductal cells located in the portal tract (PV). Insets: images of AAV-CTRL injected liver indicated 
as negative control (NC). Scale bar 50 μm.   (b) Transcript levels of Tcfeb in livers isolated 
from AAV8-TBG-CRE treated mice 4 weeks after injection. Tcfeb mRNA levels were 
normalized to the CTRL. Data are represented as mean ± SEM. ****p ≤ 0.0001 two-tailed 
Student’s t-test. (c) CK19/HNF4α immunofluorescence analysis in AAV8-TBG-CRE-treated 
and CTRL liver 4 weeks after injection showing no alteration in cell identity. Scale bar 50 μm. 
(d) Experimental design of the AAV8 injection followed by acute liver injury protocol. (e) 14-
days post DDC acute injury hepatocytes dedifferentiate in progenitor/biliary cells. (f) 
Experimental design of the AAV8 injection followed by chronic liver injury protocol (g) Gross 
appearance of AAV-injected livers from day 14 of recovery after DDC prolonged exposure. (h) 
Immunofluorescence analysis of AAV8-treated livers at day 14 of recovery after DDC diet. 
Scale bar 50 μm.   
 
Figure 8: Bile duct neoplasm in TFEB overexpressing liver.  
(a) Retrograde injection of ink revealed abnormal development of the bile duct in Tg liver 
compared to control. (b) Gross appearance of livers in Tg mice at several ages. (c) 
Quantification of liver-to-body weight ratio (LW/BW) in Tg mice at the indicated age (n=3-15). 
Values were normalized to age-matched control liver as indicated by the dashed line. Data 
are represented as mean ± SEM. ***p ≤ 0.001, ****p ≤ 0.0001 two-tailed Student’s t-test. (d) 
Immunohistochemistry and in-situ hybridization analysis for TFEB in CTRL and Tg liver at 3 
months of age. Scale bar 50 μm. (e) Histological characterization of Tg liver phenotype at 3 
months of age. Lower panel: Ki67 staining and relative quantification showing increased cell 
proliferation in Tg liver compared to CTRL. Scale bar 100 μm.  
 
